Vivet Therapeutics’ lead program, VTX-801 for Wilson Disease, was highlighted during Pfizer’s Investor Day September 15th 2020.

We are very proud of the progress in our program with IND filing and clinical initiation planned by year end.

We look forward to starting our Phase 1/2 study to demonstrate potential transformative outcomes for Wilson disease’s patients.